Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Ustach CV, Taube ME, Hurst NJ, Bhagat S, Bonfil RD, Cher ML, et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res. 2004;64(5):1722–1729. doi:10.1158/0008-5472.CAN-03-3047.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat. 2011;126(1):15–25. doi:10.1007/s10549-010-0883-2.
   PubMed Web of Science ®Google Scholar
• Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62(13):3729–3735. doi: Published July 2002, Epub 2002/07/05. PubMed PMID: 12097282.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang C, Liao G, Long J. RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model. Cancer Biol Ther. 2010;9(1):42–48. doi: 10.4161/cbt.9.1.10282
   PubMed Web of Science ®Google Scholar
• Ustach CV, Kim HR. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol. 2005;25(14):6279–6288. doi:10.1128/MCB.25.14.6279-6288.2005.
   PubMed Web of Science ®Google Scholar
• Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 2003;22(10):1501–1510. doi:10.1038/sj.onc.1206223.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kong D, Li Y, Sarkar FH. PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets. 2009;10(1):38–41. doi: 10.2174/138945009787122914
   PubMed Web of Science ®Google Scholar
• Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest. 1993;69(6):682–689. PubMed PMID: 8264231.
   PubMed Web of Science ®Google Scholar
• Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol. 1993;143(5):1377–1388. PubMed PMID: 8238254; PubMed Central PMCID: PMC1887183.
   PubMed Web of Science ®Google Scholar
• Steller EJA, Ritsma L, Raats DAE, Hoogwater FJH, Emmink BL, Govaert KM, et al. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 2011;12(9):931–937. doi:10.1038/embor.2011.129.
   PubMed Web of Science ®Google Scholar
• Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, Biesterfeld S, et al. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep. 2008;19(3):697–704. https://doi.org/10.3892/or.19.3.697
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289(5486):1938–1942. doi:10.1126/science.289.5486.1938
   PubMed Web of Science ®Google Scholar
• Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002;38(Suppl 5):S19–S27. https://doi.org/10.1016/S0959-8049(02)80599-8
   PubMed Web of Science ®Google Scholar
• Quek R, George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics. 2010;4:19–31. https://doi.org/10.2147/BTT.S4396
   PubMedGoogle Scholar
• Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol. 2005;83(1):48–56. doi:10.1111/j.1440-1711.2004.01296.x.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942–949. doi:10.1016/S1470-2045(10)70222-9.
   PubMed Web of Science ®Google Scholar
• Moawad EY. Predicting effectiveness of imatinib mesylate in tumors expressing platelet-derived growth factors (PDGF-AA, PDGF-BB), stem cell factor ligands and their respective receptors (PDGFR-alpha, PDGFR-beta, and c-kit). J Gastrointest Canc. 2015;46(3):272–283. doi:10.1007/s12029-015-9721-4.
   PubMedGoogle Scholar
• Wilkinson MJ, Fitzgerald JEF, Strauss DC, Hayes AJ, Thomas JM, Messiou C, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg. 2015;102(8):965–971. doi:10.1002/bjs.9818.
   PubMed Web of Science ®Google Scholar
• Dimberg J, Hugander A, Wagsater D. Protein expression of the chemokine, CCL28, in human colorectal cancer. Int J Oncol. 2006;28(2):315–319. https://doi.org/10.3892/ijo.28.2.315
   PubMed Web of Science ®Google Scholar
• Olsen RS, Lindh M, Vorkapic E, Andersson RE, Zar N, Löfgren S, et al. CD93 gene polymorphism is associated with disseminated colorectal cancer. Int J Colorectal Dis. 2015;30(7):883–890. doi:10.1007/s00384-015-2247-1.
   PubMed Web of Science ®Google Scholar
• Gacic J, Vorkapic E, Olsen RS, Söderberg D, Gustafsson T, Geffers R, et al. Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages. Pharmacol Rep. 2016;68(1):1–6. doi:10.1016/j.pharep.2015.05.024.
   PubMed Web of Science ®Google Scholar
• Chen J, Yuan W, Wu L, Tang Q, Xia Q, Ji J, et al. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway. Oncotarget. 2017;8(6):9961–9973. doi:10.18632/oncotarget.14283..
   PubMedGoogle Scholar
• Kaulfuss S, Seemann H, Kampe R, Meyer J, Dressel R, Konig B, et al. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget. 2013;4(7):1037–1049. doi:10.18632/oncotarget.1085.
   PubMedGoogle Scholar
• Wu Q, Hou X, Xia J, Qian X, Miele L, Sarkar FH, et al. Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev. 2013;39(6):640–646. doi:10.1016/j.ctrv.2012.11.006.
   PubMed Web of Science ®Google Scholar
• Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumor Biol. 2014;35(9):8483–8523. doi:10.1007/s13277-014-2421-z.
   PubMedGoogle Scholar
• Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HRC, et al. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 2008;68(6):1927–1934. doi:10.1158/0008-5472.CAN-07-3241.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007;67(23):11377–11385. doi:10.1158/0008-5472.CAN-07-2803.
   PubMed Web of Science ®Google Scholar
• Kundu P, Genander M, Strååt K, Classon J, Ridgway RA, Tan EH, et al. An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. Sci Transl Med. 2015;7(281):281ra44. doi:10.1126/scitranslmed.3010567.
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol. 2006;169(6):2054–2065. doi:10.2353/ajpath.2006.060653.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Hwang J, Magbanua MJM, Watt L, Beumer JH, Christner SM, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013;109(7):1725–1734. doi:10.1038/bjc.2013.553.
   PubMed Web of Science ®Google Scholar
• Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, et al. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer. 2013;109(6):1408–1413. doi:10.1038/bjc.2013.409.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, et al. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer–a dose-escalation Phase I trial. Cancer. 2007;109(9):1897–1904. doi:10.1002/cncr.22622.
   PubMed Web of Science ®Google Scholar
• Bergsten E, Uutela M, Li X, Pietras K, Östman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001;3(5):512–516. doi:10.1038/35074588.
   PubMed Web of Science ®Google Scholar
• Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, et al. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol. 1997;172(1):1–11. doi:10.1002/(SICI)1097-4652(199707)172:1 < 1::AID-JCP1 > 3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998;19(1):49–53. doi: 10.1093/carcin/19.1.49
   PubMed Web of Science ®Google Scholar
• Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, Hsi LC, et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res. 2001;267(1):73–80. doi:10.1006/excr.2001.5233.
   PubMed Web of Science ®Google Scholar
• Han S, Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? AntiCancer Drugs. 2007;18(3):237–244. doi:10.1097/CAD.0b013e328011e67d.
   PubMed Web of Science ®Google Scholar